Transkaryotic(tktx) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Transkaryotic(tktx)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: trevor john wilkinson who started this subject	1/2/2001 9:18:14 AM
From: Souze	of 122

TKT Files IND to Begin Clinical Testing of Iduronate-2- Sulfatase for the Treatment of Hunter Syndrome PR Newswire, 01/2/2001 08:30 /FROM PR NEWSWIRE BOSTON 617-482-5355/ [STK] TKTX [IN] MTC BIO [SU] TO BUSINESS AND MEDICAL EDITORS: TKT Files IND to Begin Clinical Testing of Iduronate-2-Sulfatase for the Treatment of Hunter Syndrome CAMBRIDGE, Mass., Jan. 2 /PRNewswire/ -- Transkaryotic Therapies, Inc. (NASDAQ:TKTX) today announced that it has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) to commence a Phase I/II clinical trial of Company's Niche Protein(TM) product, iduronate-2-sulfatase (I2S), an enzyme replacement therapy for the treatment of Hunter syndrome. ----- snipped ----------

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next